Neuphoria Therapeutics Inc. Other Income and Expense
Neuphoria Therapeutics Inc. (NEUP) reported Other Income and Expense of $2.86 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-09-18
- Neuphoria Therapeutics Inc. nonoperating income (expense) for the quarter ending 2026-06-30 was $586.67K.
- Neuphoria Therapeutics Inc. nonoperating income (expense) for the quarter ending 2026-03-31 was $671.79K.
- Neuphoria Therapeutics Inc. nonoperating income (expense) for the quarter ending 2025-12-31 was $5.89M, a 232.44% increase year-over-year.
- Neuphoria Therapeutics Inc. nonoperating income (expense) for the quarter ending 2025-09-30 was -$4.29M, a 263.02% decline year-over-year.
- Neuphoria Therapeutics Inc. nonoperating income (expense) for fiscal 2026 was $2.86M, a 882.49% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. nonoperating income (expense) for fiscal 2025 was $291.09K, a 87.41% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. nonoperating income (expense) for fiscal 2024 was $2.31M, a 400.49% increase from fiscal 2023.
- Neuphoria Therapeutics Inc. nonoperating income (expense) for fiscal 2023 was $462.13K.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $586.67K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $1.26M derived: sum of 2 quarters · filed 2026-09-18 | $7.15M derived: sum of 3 quarters · filed 2026-09-18 | $2.86M 10-K · filed 2026-09-18 |
| 2026-03-31 | $671.79K 10-Q · filed 2026-05-15 | $6.56M derived: sum of 2 quarters · filed 2026-05-15 | $2.27M 10-Q · filed 2026-05-15 | -$1.04M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | $5.89M 10-Q · filed 2026-02-17 | $1.60M 10-Q · filed 2026-02-17 | -$1.71M derived: sum of 3 quarters · filed 2026-09-18 | -$2.51M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$4.29M 10-Q · filed 2025-11-14 | -$7.60M derived: sum of 2 quarters · filed 2026-09-18 | -$8.40M derived: sum of 3 quarters · filed 2026-09-18 | -$6.63M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$3.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$4.11M derived: sum of 2 quarters · filed 2026-09-18 | -$2.34M derived: sum of 3 quarters · filed 2026-09-18 | $291.09K 10-K · filed 2026-09-18 |
| 2025-03-31 | -$796.22K 10-Q · filed 2026-05-15 | $975.55K derived: sum of 2 quarters · filed 2026-05-15 | $3.61M 10-Q · filed 2026-05-15 | $6.36M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.77M 10-Q · filed 2026-02-17 | $4.40M 10-Q · filed 2026-02-17 | $7.16M derived: sum of 3 quarters · filed 2026-02-17 | $6.79M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | $2.63M 10-Q · filed 2025-11-14 | $5.39M derived: sum of 2 quarters · filed 2025-11-14 | $5.02M derived: sum of 3 quarters · filed 2025-11-14 | $4.98M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $2.39M derived: sum of 2 quarters · filed 2025-09-29 | $2.35M derived: sum of 3 quarters · filed 2025-09-29 | $2.31M 10-K · filed 2025-09-29 |
| 2024-03-31 | -$367.73K 10-Q · filed 2025-05-20 | -$404.09K derived: sum of 2 quarters · filed 2025-05-20 | -$443.84K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$36.36K 10-Q · filed 2025-02-14 | -$76.11K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$39.75K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $462.13K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |